Press release

FEops secures additional capital from the EIC Fund

28 October 2022

FEops, a cloud-based digital health player in the structural heart space, announces that it has secured a convertible loan of € 3.3 million from its current investors and the EIC Fund in preparation of a larger capital round.

“We were already very proud to be selected in the highly competitive EIC Accelerator programme in 2019 and to have received a grant of EUR 3.2m. It is a seal of quality that the European Commission chooses to continue supporting us, and is now taking the step to provide equity under the form of a convertible loan with the potential of becoming a shareholder.” said Isabelle Decroos, CFO of FEops.

FEops HEARTguide is CE-marked under MDR for its TAVI and LAA workflow and FDA cleared for its LAA workflow. Clinical data from the landmark PREDICT-LAA prospective, multicenter, randomized controlled trial, presented last month at the TCT convention, conclude that FEops HEARTguide improves both procedure efficiency and clinical outcome significantly for LAA occlusion procedures.

This additional investment supports FEops in its mission to continue spearheading AI-enabled digital twin solutions to help treatment of heart disease patients with the appropriate technology at the right time and enables further expansion of FEops’ established digital twin technology in other indications.

More information on FEops website.